Clinical Trial Center of the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
School of Public Foundation, Bengbu Medical University, Bengbu, Anhui, China.
Cell Cycle. 2023 Dec-Dec;22(23-24):2622-2636. doi: 10.1080/15384101.2023.2299624. Epub 2024 Jan 2.
A protein called cleavage-stimulating factor subunit 2 (CSTF2, additionally called CSTF-64) binds RNA and is needed for the cleavage and polyadenylation of mRNA. CSTF2 is an important component subunit of the cleavage stimulating factor (CSTF), which is located on the X chromosome and encodes 557 amino acids. There is compelling evidence linking elevated CSTF2 expression to the pathological advancement of cancer and on its impact on the clinical aspects of the disease. The progression of cancers, including hepatocellular carcinoma, melanoma, prostate cancer, breast cancer, and pancreatic cancer, is correlated with the upregulation of CSTF2 expression. This review provides a fresh perspective on the investigation of the associations between CSTF2 and various malignancies and highlights current studies on the regulation of CSTF2. In particular, the mechanism of action and potential clinical applications of CSTF2 in cancer suggest that CSTF2 can serve as a new biomarker and individualized treatment target for a variety of cancer types.
一种名为切割刺激因子亚基 2(CSTF2,也称为 CSTF-64)的蛋白质与 RNA 结合,是 mRNA 切割和多聚腺苷酸化所必需的。CSTF2 是切割刺激因子(CSTF)的一个重要组成亚基,位于 X 染色体上,编码 557 个氨基酸。有强有力的证据表明 CSTF2 表达的升高与癌症的病理进展及其对疾病临床方面的影响有关。包括肝细胞癌、黑色素瘤、前列腺癌、乳腺癌和胰腺癌在内的癌症的进展与 CSTF2 表达的上调有关。这篇综述提供了一个新的视角来研究 CSTF2 与各种恶性肿瘤之间的关系,并强调了目前关于 CSTF2 调控的研究。特别是,CSTF2 在癌症中的作用机制及其潜在的临床应用表明,CSTF2 可以作为多种癌症类型的新型生物标志物和个体化治疗靶点。